Hims & Hers Health Sees Unusually High Options Volume (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of unusually large options trading on Monday. Stock traders acquired 67,660 call options on the company. This represents an increase of 52% compared to the typical volume of 44,492 call options.

Hims & Hers Health Trading Up 16.3 %

NYSE:HIMS traded up $4.13 on Monday, hitting $29.46. The company had a trading volume of 18,890,694 shares, compared to its average volume of 9,554,153. The firm has a 50 day moving average of $20.55 and a two-hundred day moving average of $19.31. The stock has a market capitalization of $6.44 billion, a price-to-earnings ratio of 66.64 and a beta of 1.06. Hims & Hers Health has a 52 week low of $8.09 and a 52 week high of $30.44.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) earnings per share. As a group, equities analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Analysts Set New Price Targets

HIMS has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Needham & Company LLC assumed coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. TD Cowen reissued a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $20.71.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 2,345 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the transaction, the insider now directly owns 159,796 shares of the company’s stock, valued at $2,341,011.40. This represents a 1.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Melissa Baird sold 58,750 shares of Hims & Hers Health stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00. Following the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at approximately $13,258,692.64. This represents a 8.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,056,183 shares of company stock worth $21,501,682 over the last ninety days. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HIMS. Sei Investments Co. raised its position in shares of Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after purchasing an additional 37,890 shares during the period. Vanguard Group Inc. increased its holdings in Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after acquiring an additional 136,907 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Hims & Hers Health by 239.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock worth $2,606,000 after buying an additional 118,848 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of Hims & Hers Health during the first quarter worth about $421,000. Finally, Bayesian Capital Management LP bought a new stake in Hims & Hers Health during the first quarter worth about $1,770,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.